Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Global coalition launched to protect against epidemics
vaccine
CEPI aims to lessen the amount of time it takes to develop new vaccines.
Project aims to reduce time it takes to develop new vaccines

A new global partnership to prevent epidemics with vaccines has launched at the World Economic Forum in Davos, Switzerland.

The Coalition for Epidemic Preparedness (CEPI) seeks to outsmart emerging infectious diseases by developing safe and effective vaccines before they emerge.

The project is funded by the governments of Germany, Norway, Japan, the Bill and Melinda Gates Foundation and the Wellcome Trust.

“Ebola and Zika showed that the world is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics. Without investments in research and development, we will remain unequipped when we face the next threat,” said Bill Gates, chair of the Bill and Melinda Gates Foundation.

“The ability to rapidly develop and deliver vaccines when new ‘unknown’ diseases emerge offers our best hope to outpace outbreaks, save lives and avert disastrous economic consequences. CEPI is a great example of how supporting innovation and R&D can help the world to address some of its most pressing health challenges.”

CEPI also aims to lessen the amount of time it takes to develop new vaccines by capitalising on developments in adaptable vaccine technology and investing in facilities that could respond quickly to previously unknown pathogens.

So far, the partnership has already raised half of the $1bn it needs for its first five years. It is now calling on researchers and companies around the world to support the development of the development of vaccines against its first target diseases.

To start, CEPI will target the MERS-CoV, Lassa and Nipah viruses. It aims to develop two promising vaccine candidates against each of these diseases before they cause serious epidemics.

CEPI will also look for potential support for vaccines against the various strains of Zika, Ebola ad Marburg viruses.

“We know from Ebola, Zika and SARS that epidemics are among the significant threats we face to life, health and prosperity,” said Dr Jeremy Farrar, director of the Wellcome Trust.

“Vaccines can protect us, but we’ve done too little to develop them as an insurance policy. CEPI is our chance to learn the lessons of recent tragedies, and outsmart epidemics with new vaccine defences. If others join us in supporting CEPI, we can realise our goal of creating a safer world.” 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.